Carisma Therapeutics Provides Corporate Updates
Carisma Therapeutics (CARM) Prnewswire·2025-03-31 20:30Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn Pipeline Updates Fibrosis Ex Vivo Oncology In Vivo Program (Moderna Collaboration) Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA/LNP approach, our product candidate, CT-2401, aims to reverse fibrotic disease and improve the outcomes of patients with advance ...